• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacognosy Research >UP1304, a Botanical Composition Containing Two Standardized Extracts of Curcuma longa and Morus alba, Mitigates Pain and Inflammation in Adjuvant-induced Arthritic Rats
【24h】

UP1304, a Botanical Composition Containing Two Standardized Extracts of Curcuma longa and Morus alba, Mitigates Pain and Inflammation in Adjuvant-induced Arthritic Rats

机译：UP1304，一种植物组合物，包含姜黄和桑树的两种标准化提取物，可减轻佐剂诱发的关节炎大鼠的疼痛和炎症

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Though, the initial etiologies of arthritis are multifactorial, clinically, patients share pain as the prime complaints. Present day pain relief therapeutics heavily relies on the use of prescription and over the counter nonsteroidal anti-inflammatory drugs as the first line of defense where their long-term usage causes gastrointestinal and cardiovascular-related side effects. Hence, the need for evidence-based safer and efficacious alternatives from natural sources to overcome the most prominent and disabling symptoms of arthritis is an overdue. Here, we evaluated the anti-inflammatory and analgesic effect of UP1304, a composition that contains a standardized blend of two extracts from the rhizome of Curcuma longa and the root bark of Morus alba in adjuvant-induced arthritis models in rats. Materials and Methods: The anti-inflammatory and analgesic effects of the botanical composition were demonstrated in adjuvant-induced arthritis models in rats with oral dose ranges of 50–200 mg/kg. Ibuprofen at a dose of 100 mg/kg was used as a reference compound. Ex vivo sulfated glycosaminoglycan inhibition assays were performed. Results: Statistically significant improvements in pain resistance, suppression of paw edema and ankle thickness were observed in animals treated with UP1304 compared to vehicle-treated diseased rats. These results were similar to those achieved by ibuprofen treatment. Inhibitions of proteoglycan degradation were observed in a range of 37.5–61.7% for concentration of UP1304 at 50–200 μg/mL when compared to interleukin-1α-exposed untreated explants. Conclusions: These data suggest that UP1304, for its analgesic and anti-inflammatory effects, could potentially be considered agent of botanical origin for the improvement of arthritis associated symptoms. SUMMARY Pain is one of the cardinal signs of arthritis. Long term applications of commonly used non-steroidal anti-inflammatory drugs for pain relief are associated with cardiovascular and gastrointestinal side effects. Cartilage degradation evidenced as glycosaminoglycan loss from articular cartilage into the synovial fluid has been reported in arthritis patients. Adjuvant–induced arthritis model in rats are among the widely used models for efficacy evaluation of nutraceuticals. Efficacy of UP1304, a composition containing a blend of two standardized extracts from the rhizome of Curcuma longa and root bark of Morus alba, was evaluated in adjuvant–induced arthritis model in rats and in glycosaminoglycan releasing inhibition assays. UP1304 demonstrated its enhanced significance by improving the major cardinal signs of arthritis in vivo and ex vivo. UP1304 could potentially be considered as a dietary supplement product for the management of arthritis.
机译：背景：尽管关节炎的最初病因是多方面的，但在临床上，患者的主要症状是疼痛。当今的止痛疗法在很大程度上依赖处方药和非处方非甾体类抗炎药，因为长期使用它们会引起胃肠道和心血管相关的副作用。因此，对于克服自然界最突出和致残性关节炎症状的自然来源的循证安全和有效替代品的需求已经过时了。在这里，我们评估了UP1304的抗炎和镇痛作用，UP1304是一种在大鼠佐剂诱发的关节炎模型中包含姜黄根茎和桑树根皮的两种提取物的标准混合物的组合物。材料和方法：在口服剂量为50-200 mg / kg的大鼠的佐剂诱发的关节炎模型中证明了该植物性组合物的抗炎和镇痛作用。 100 mg / kg剂量的布洛芬用作参考化合物。进行了离体硫酸化的糖胺聚糖抑制试验。结果：与用赋形剂处理的患病大鼠相比，用UP1304处理的动物在疼痛耐受性，抑制脚掌浮肿和踝关节厚度方面具有统计学上的显着改善。这些结果与布洛芬治疗所获得的结果相似。与暴露于白介素-1α的未处理外植体相比，在50-200μg/ mL的UP1304浓度下，蛋白聚糖降解的抑制作用范围为37.5-61.7％。结论：这些数据表明，UP1304具有止痛和抗炎作用，可能被认为是植物源性药物，可改善关节炎相关症状。小结疼痛是关节炎的主要症状之一。长期使用非甾体抗炎药缓解疼痛与心血管和胃肠道副作用有关。在关节炎患者中，已经报道了软骨降解被证实为糖胺聚糖从关节软骨损失到滑液中。在大鼠中，佐剂诱发的关节炎模型是用于营养保健品功效评估的广泛使用的模型之一。在佐剂诱导的大鼠关节炎模型和糖胺聚糖释放抑制试验中评估了UP1304（一种由姜黄根茎和桑树根皮组成的标准提取物的混合物）组成的功效。 UP1304通过改善体内和离体关节炎的主要基本体征显示出其增强的意义。 UP1304可能被认为是治疗关节炎的膳食补充产品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号